Galecto Management
Management criteria checks 3/4
Galecto's CEO is Hans Schambye, appointed in Jan 2020, has a tenure of 4.92 years. total yearly compensation is $965.12K, comprised of 52.4% salary and 47.6% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $11.37K. The average tenure of the management team and the board of directors is 3.6 years and 4.6 years respectively.
Key information
Hans Schambye
Chief executive officer
US$965.1k
Total compensation
CEO salary percentage | 52.4% |
CEO tenure | 4.9yrs |
CEO ownership | 0.2% |
Management average tenure | 3.6yrs |
Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
Jan 10Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely
May 17Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
Feb 01Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer
Oct 19Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Oct 19Galecto GAAP EPS of -$0.67 beats by $0.02
Jul 29We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Jun 30Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?
Mar 10Galecto: Selling At Cash Value
Dec 19We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Nov 18Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Jul 07Galecto EPS misses by $0.07
May 04We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth
Mar 23Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?
Jan 29Galecto EPS misses by $41.65
Dec 11CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$21m |
Jun 30 2024 | n/a | n/a | -US$25m |
Mar 31 2024 | n/a | n/a | -US$31m |
Dec 31 2023 | US$965k | US$506k | -US$38m |
Sep 30 2023 | n/a | n/a | -US$46m |
Jun 30 2023 | n/a | n/a | -US$52m |
Mar 31 2023 | n/a | n/a | -US$58m |
Dec 31 2022 | US$1m | US$473k | -US$62m |
Sep 30 2022 | n/a | n/a | -US$61m |
Jun 30 2022 | n/a | n/a | -US$60m |
Mar 31 2022 | n/a | n/a | -US$55m |
Dec 31 2021 | US$3m | US$512k | -US$52m |
Sep 30 2021 | n/a | n/a | -US$42m |
Jun 30 2021 | n/a | n/a | -US$44m |
Mar 31 2021 | n/a | n/a | -US$43m |
Dec 31 2020 | US$4m | US$387k | -US$35m |
Sep 30 2020 | n/a | n/a | -US$57m |
Jun 30 2020 | n/a | n/a | -US$48m |
Mar 31 2020 | n/a | n/a | -US$42m |
Dec 31 2019 | US$479k | US$360k | -US$42m |
Compensation vs Market: Hans's total compensation ($USD965.12K) is above average for companies of similar size in the US market ($USD650.40K).
Compensation vs Earnings: Hans's compensation has been consistent with company performance over the past year.
CEO
Hans Schambye (58 yo)
4.9yrs
Tenure
US$965,115
Compensation
Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer and Director at Galecto, Inc. since 2020 a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 4.9yrs | US$965.12k | 0.16% $ 11.4k | |
Senior VP | 3.6yrs | US$554.39k | 0.012% $ 867.3 | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Interim Chief Financial Officer | less than a year | no data | no data |
3.6yrs
Average Tenure
51yo
Average Age
Experienced Management: GLTO's management team is considered experienced (3.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 4.9yrs | US$965.12k | 0.16% $ 11.4k | |
Independent Chairman of the Board | 4.9yrs | US$155.19k | 0.029% $ 2.1k | |
Independent Director | 4.6yrs | US$148.84k | 0% $ 0 | |
Independent Director | 4.6yrs | US$78.85k | 0.015% $ 1.0k | |
Independent Director | 3.9yrs | US$83.85k | 0% $ 0 | |
Independent Director | 4.1yrs | US$86.35k | 0% $ 0 | |
Member of Clinical Advisory Board – Liver cirrhosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data | |
Member of the Clinical Advisory Board - Myelofibrosis | no data | no data | no data |
4.6yrs
Average Tenure
61.5yo
Average Age
Experienced Board: GLTO's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 16:45 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galecto, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Kristen Kluska | Cantor Fitzgerald & Co. |
Thomas Smith | Leerink Partners LLC |